Transplantation
NEW YORK (June 4, 2009) -- For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.
NEW YORK (June 4, 2009) -- NewYork-Presbyterian Hospital/Columbia University Medical Center physician-scientists presented new research at the 2009 American Transplant Congress in Boston, May 30 to June 3. Topics included minimizing steroid exposure for liver transplant patients with hepatitis C; hypothermic machine perfusion vs.
CINCINNATI -- Researchers at the University of Cincinnati (UC) have discovered a protein in the lungs that can help in determining progression of the rare lung disease Idiopathic Pulmonary Fibrosis (IPF).
BOSTON -- Early results from a Mayo Clinic (http://www.mayoclinic.org/transplantcenter-rst/) research study demonstrate the effectiveness of a new approach to blocking an important part of the immune system that causes severe damage to some kidney transplants.
The latest research in liver disease being presented at Digestive Disease Week® 2009 (DDW®) has important implications for tracking disease development in patients and for current and future transplant recipients. Researchers are making great strides in diagnosing and treating liver disease.
A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston.
Boston, MA ? June 1, 2009 ? REGiMMUNE Corporation today announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD).
A blood-pressure medicine has been shown to reverse the effects of early-stage liver failure in some patients.
Newcastle University researchers analysed a small clinical trial of losartan, a drug normally prescribed for hypertension, on 14 patients in Spain, who had Hepatitis C.
NewYork-Presbyterian Hospital/Weill Cornell Medical Center physician-scientists are presenting exciting new research at the 2009 American Transplant Congress in Boston from May 30 to June 3.
Viewing a video showing a patient with advanced dementia interacting with family and caregivers may help elderly patients plan for end-of-life care, according to a study led by Massachusetts General Hospital (MGH) researchers.
Two new studies address donor factors that could affect outcomes for liver transplant recipients, particularly those with chronic hepatitis C (HCV). One found that donor steatosis, or fat in the liver, does not affect liver disease progression or three-year survival in recipients with or without HCV.
BUFFALO, N.Y. -- University at Buffalo researchers have demonstrated for the first time that injecting adult bone marrow stem cells into skeletal muscle can repair cardiac tissue, reversing heart failure.
A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.
Once placed into a patient's body, stem cells intended to treat or cure a disease could end up wreaking havoc simply because they are no longer under the control of the clinician.
CINCINNATI--After comparing two patient cancer registries--one featuring transplant patients and the other the general population--researchers at the University of Cincinnati (UC) have found that transplant patients experience worse outcomes from cancer.
These results will be published in the May 15, 2009, edition of the journal Transplantation, which is currently in press.
